India Diabetes Care Drugs Market is Segmented by Drugs (Oral Anti-diabetic Drugs, Insulin, Non-insulin Injectable Drugs, and Combination Drugs). The report offers the value (in USD million) for the above segments.

India Diabetes Care Drugs Market Size

Study Period: 2018 - 2028
CAGR: > 3.5 %

Major Players


*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and it's growth?

India Diabetes Care Drugs Market Analysis

The India Diabetes Care Drugs Market is expected to register a CAGR greater than 3.5% forecast period, 2022-2027.

In India, COVID-19 infections, which began around two years ago, have contributed to a nearly 25% increase. With Over 80 million diabetics, India is commonly referred to be the diabetes capital. COVID, a viral infection that generates a variety of inflammatory reactions, has been linked to several recurring and new health problems, including hypoxia, weakness, weight loss, hair loss, myocarditis, and thyroid problems. However, diabetes is said to be one of the most prevalent side effects of the infectious condition. According to Dr. Anoop Misra, a senior endocrinologist from Delhi, the prevalence of new-onset diabetes and thyroid dysfunction in Covid-19 patients has been observed across countries. He speculated that the explanations may be "severe impacts of cytokine surge" (a strong immunological reaction reported in certain Covid patients) and/or "some unfurling of autoimmunity" (when the body's immune system mistakes and targets the body's own tissues and organs).

Insulin has a substantial market share in the pharmaceutical industry. Insulin is used by around 100 million people globally, including all patients with Type 1 diabetes and 10% to 25% of people with Type 2 diabetes. Insulin manufacturing is highly complicated, with just a few insulin producers on the market. As a result, there is tremendous competition among these companies, which are always seeking to meet patient requests by offering the highest-quality insulin.

India Diabetes Care Drugs Industry Segmentation

Diabetes or diabetes mellitus describes a group of metabolic disorders characterized by a high blood sugar level in a person. With diabetes, the body either does not produce enough insulin or the body's cells do not respond properly to insulin or both. The diabetes care drugs market is segmented by drugs into Insulin (Basal Or Long-Acting, Bolus Or Fast-Acting, Traditional Human Insulin Drugs, and Insulin Biosimilars), Oral Anti-Diabetic Drugs (Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors), Non-Insulin Injectable Drugs (GLP-1 Receptor Agonists, and Amylin Analogue), and Combination Drugs (Combination Insulin, Oral Combination).

Oral Anti-diabetic drugs (Value and Volume, 2016-2027)
Alpha-Glucosidase Inhibitors
Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist
SGLT-2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Galvus (Vildagliptin)
Insulins (Value and Volume, 2016-2027)
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Combination drugs (Value and Volume, 2016-2027)
Insulin combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combinations
Janumet (Sitagliptin and Metformin)
Non-Insulin Injectable drugs (Value and Volume, 2016-2027)
GLP-1 receptor agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)

Report scope can be customized per your requirements. Click here.

India Diabetes Care Drugs Market Trends

This section covers the major market trends shaping the India Diabetes Care Drugs Market according to our research experts:

Oral-Anti Diabetes Drugs Segment is Having the Highest Market Share in 2021

The Oral-Anti Diabetes Drugs segment is expected to increase with a CAGR of over 3% during the forecast period, mainly due to the demand from the diabetes population, which was more than 82 million by the end of 2022.

Diabetes is a disorder for which there is no cure. With the present arsenal, it is an illness that impacts us for the rest of patients' lives. Individuals face a significant financial, social, and emotional burden beginning at the age of 30 and continuing into their 90s. According to all current guidelines in India, metformin should be the first option among oral antidiabetic medicines at the outset of diabetes.

However, a review of the literature from throughout the world finds that metformin is used in a variety of ways in the early stages of diabetes. Sharma et al. found a changing trend in 55% of metformin-treated individuals. The fraction of individuals on metformin remains stable from 0 to 20 years of diabetes. The proportion of sulfonylurea and dipeptidyl peptidase-4 inhibitors (DPP4i) increases from 23.12% and 22.5% in 0-5 years of diabetes to 70.77% and 60% in 10-15 years of diabetes. Following that, the proportion of sulfonylurea and DPP4i remains constant. As the use of sulfonylureas and DPP4i reaches a plateau, the use of insulin and sodium/glucose cotransporter 2 inhibitors increases. From 5 to 10 years of diabetes duration to 20+ years of diabetes duration, the proportion of alpha-glucosidase inhibitors increases somewhat. Thiazolidinediones and glucagon-like peptide-1 receptor agonists have a small proportion in contemporary practice and the given patient population.

Through the Indian government’s encouragement, the usage of Drugs increased over the forecast period.

India Drugs

The rising prevalence of diabetes in India is boosting the country's diabetes drugs market.

In India, it is anticipated to exceed 134 million by 2045. Approximately 57% of these people are still undiagnosed. Type 2 diabetes, which accounts for most cases, can result in multiorgan problems, which are roughly classified as microvascular and macrovascular complications. These problems are a key cause of increased early morbidity and death in diabetics, resulting in decreased life expectancy and a huge financial load on the Indian health care system. Diabetes risk factors include race, age, obesity, physical inactivity, a poor diet, and behavioral behaviors, as well as genetics and family history. Controlling blood sugar, blood pressure, and blood lipid levels can help to avoid or postpone the onset of diabetic complications. Diabetes prevention and management pose a significant challenge in India due to a number of issues and barriers, including a lack of a multisectoral approach, surveillance data, awareness of diabetes, its risk factors and complications, and access to health care settings, access to affordable medicines, and so on.

People living in cities and metropolitan regions in India are more likely than ever before to get diabetes, according to the 2021 assessment. This is due, in part, to cities encouraging a lifestyle that might raise a person's BMI (BMI). A greater BMI is a risk factor for diabetes. Rural India is also seeing an increase in type 2 diabetes occurrences. Diabetes is perceived as a "new" ailment in rural places, and public understanding of the condition is poor.

Diabetes cases are on the rise as the country undergoes urbanization, which means that more people are migrating to larger cities for work. Sedentary living habits are promoted in urbanized regions and cities, which is a risk factor for both obesity and diabetes. South Asian ancestors' bodies respond differently to sugary and fatty diets than European ancestors' bodies, and as processed Western foods become more popular in India, so does the risk of diabetes.

Thus, owing to the above factors it is expected to drive the market growth over the forecast period.


India Diabetes Care Drugs Industry Overview

The India diabetes drugs market is moderately fragmented, with few significant and generic players. The insulin drugs and Sglt-2 drugs market are dominated by a few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, to increase their market shares, players are tapping into new markets, especially emerging economies where the demand is very high compared to the supply.

India Diabetes Care Drugs Market Leaders

  1. Eli Lilly

  2. Boehringer Ingelheim

  3. Astrazeneca

  4. Sanofi

  5. NovoNordisk

*Disclaimer: Major Players sorted in no particular order


India Diabetes Care Drugs Market News

  • In Jul 2022, Glenmark's announced the launch of sitagliptin and its fixed dose combinations (FDCs) for adults with Type-2 diabetes in India. The company has introduced 8 different combinations of sitagliptin-based drugs under the brand name SITAZIT and its variants at affordable prices. Glenmark's SITAZIT and its variants will play an instrumental role in raising the accessibility of sitagliptin to type-2 diabetic patients, which is considered the gold standard molecule in DPP4 inhibitor therapy. It will help the patients to manage their glycemic levels effectively and bring better compliance.
  • In Jan 2022, Novo Nordisk India launched an oral formulation for an anti-diabetes drug that was available only as injections and claimed the new drug can help better control blood sugar levels and weight in adults with type-2 diabetes.

India Diabetes Care Drugs Market Report - Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 Oral Anti-diabetic drugs (Value and Volume, 2016-2027)

      1. 5.1.1 Biguanides

        1. Metformin

      2. 5.1.2 Alpha-Glucosidase Inhibitors

        1. Alpha-Glucosidase Inhibitors

      3. 5.1.3 Dopamine D2 receptor agonist

        1. Bromocriptin

      4. 5.1.4 SGLT-2 inhibitors

        1. Invokana (Canagliflozin)

        2. Jardiance (Empagliflozin)

        3. Farxiga/Forxiga (Dapagliflozin)

        4. Suglat (Ipragliflozin)

      5. 5.1.5 DPP-4 inhibitors

        1. Onglyza (Saxagliptin)

        2. Tradjenta (Linagliptin)

        3. Vipidia/Nesina(Alogliptin)

        4. Galvus (Vildagliptin)

      6. 5.1.6 Sulfonylureas

        1. Sulfonylureas

      7. 5.1.7 Meglitinides

        1. Meglitinides

    2. 5.2 Insulins (Value and Volume, 2016-2027)

      1. 5.2.1 Basal or Long Acting Insulins

        1. Lantus (Insulin Glargine)

        2. Levemir (Insulin Detemir)

        3. Toujeo (Insulin Glargine)

        4. Tresiba (Insulin Degludec)

        5. Basaglar (Insulin Glargine)

      2. 5.2.2 Bolus or Fast Acting Insulins

        1. NovoRapid/Novolog (Insulin Aspart)

        2. Humalog (Insulin Lispro)

        3. Apidra (Insulin Glulisine)

      3. 5.2.3 Traditional Human Insulins

        1. Novolin/Actrapid/Insulatard

        2. Humulin

        3. Insuman

      4. 5.2.4 Biosimilar Insulins

        1. Insulin Glargine Biosimilars

        2. Human Insulin Biosimilars

    3. 5.3 Combination drugs (Value and Volume, 2016-2027)

      1. 5.3.1 Insulin combinations

        1. NovoMix (Biphasic Insulin Aspart)

        2. Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. Xultophy (Insulin Degludec and Liraglutide)

      2. 5.3.2 Oral Combinations

        1. Janumet (Sitagliptin and Metformin)

    4. 5.4 Non-Insulin Injectable drugs (Value and Volume, 2016-2027)

      1. 5.4.1 GLP-1 receptor agonists

        1. Victoza (Liraglutide)

        2. Byetta (Exenatide)

        3. Bydureon (Exenatide)

        4. Trulicity (Dulaglutide)

        5. Lyxumia (Lixisenatide)

      2. 5.4.2 Amylin Analogue

        1. Symlin (Pramlintide)


    1. 6.1 Type-1 Diabetic Population (2016-2027)

    2. 6.2 Type-2 Diabetic Population (2016-2027)



      1. 7.1.1 Takeda

      2. 7.1.2 Novo Nordisk

      3. 7.1.3 Pfizer

      4. 7.1.4 Eli Lilly

      5. 7.1.5 Janssen Pharmaceuticals

      6. 7.1.6 Astellas

      7. 7.1.7 Boehringer Ingelheim

      8. 7.1.8 Merck And Co.

      9. 7.1.9 AstraZeneca

      10. 7.1.10 Bristol Myers Squibb

      11. 7.1.11 Novartis

      12. 7.1.12 Sanofi


You can also purchase parts of this report. Do you want to check out a section wise price list?

India Diabetes Care Drugs Market Research FAQs

The India Diabetes Care Drugs Market is studied from 2018 - 2028.

The India Diabetes Care Drugs Market is growing at a CAGR of >3.5% over the next 5 years.

The India Diabetes Care Drugs Market is valued at 1 Billion USD in 2018.

The India Diabetes Care Drugs Market is valued at 1 Billion USD in 2028.

Eli Lilly, Boehringer Ingelheim, Astrazeneca, Sanofi, NovoNordisk are the major companies operating in India Diabetes Care Drugs Market.

India Diabetes Care Drugs Industry Report

Statistics for the 2023 India Diabetes Care Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. India Diabetes Care Drugs analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!